The treatment paradigm for Retinitis Pigmentosa (RP), a group of rare genetic disorders causing progressive vision loss, is ...

W. L. Gore & Associates, Inc. ("Gore"), a global materials science company, recently announced the commercial launch of the 0 ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

Sunir Garg, MD, discusses a challenge in ophthalmological procedures: patient discomfort during intravitreal injections ...

One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the ...

Diabetic retinopathy affects almost 10 million people in the US and is the third FDA-approved indication for Susvimo, which is also approved for treating neovascular or ‘wet’ age-related macular ...

In patients with diabetic retinopathy, obstructive sleep apnea increases the risk for proliferative diabetic retinopathy, intravitreal injection, and stroke.

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

Sylentis recently announced topline results from the SYL1801_II phase 2a study investigating SYL1801 for the treatment of ...